Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qingxuan Zhike Granule plus oseltamivir for children with influenza
ChiCTR2300070500Phase 4Not yet recruiting
- Sponsor
- Yunnan Provincial Hospital of Traditional Chinese Medicine
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of qingxuan zhike granule and oseltamivir in influenza (2 arms), sponsored by Yunnan Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Canadian Acute Respiratory Disease and Influenza Scale symptom score area under the curve at Day 7, Time to clinical recovery at Day 7 and 2 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
qingxuan zhike granuleoseltamivir
03
Conditions
influenza
Beyond the preview
Go deeper on ChiCTR2300070500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070500.